Tremfya

Tremfya (guselkumab) is a prescription medication used to treat moderate to severe plaque psoriasis and active psoriatic arthritis. This biologic therapy targets specific immune pathways to reduce inflammation. It is administered by healthcare professionals via injection. Always consult a healthcare provider for suitability.

Tremfya is prescribed for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. It is also used to treat active psoriatic arthritis in adults, helping to reduce joint damage and improve physical function. Guselkumab works by targeting interleukin-23, a protein involved in the inflammatory process. Patients often ask, what is guselkumab used for and whether it can help with their condition.

Many patients experience reduced skin plaques and joint pain after starting Tremfya. Skin improvements may include less redness, scaling, and thickness of affected areas. For psoriatic arthritis, some users report better mobility and fewer swollen or tender joints. Individual responses vary, and results typically appear over several weeks of consistent treatment.

Tremfya should only be used under medical supervision due to its injectable nature. Patients with active infections should discuss risks with their doctor before starting treatment. Regular monitoring may be required to assess response and detect any changes in health. Keep this medication stored as directed by the manufacturer.

Limited data exist on drug interactions with guselkumab, but live vaccines are not recommended during treatment. Immunosuppressants or biologics used concurrently may increase infection risk. Always inform your healthcare provider about all medications, including over-the-counter and herbal products. Avoid starting new treatments without consulting a medical professional.